Logo image of XOMAO

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) Stock Overview

NASDAQ:XOMAO - US98419J4040

25.4999 USD
-0.01 (-0.03%)
Last: 9/5/2025, 4:30:02 PM

XOMAO Key Statistics, Chart & Performance

Key Statistics
52 Week High25.87
52 Week Low23.32
Market Cap308.29M
Shares12.09M
Float11.93M
Yearly Dividend0.47
Dividend Yield8.24%
EPS(TTM)-1.54
PEN/A
Fwd PE140.71
Earnings (Next)11-05 2025-11-05
IPO06-06 1986-06-06
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


XOMAO short term performance overview.The bars show the price performance of XOMAO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 0.2 -0.2 0.4 0.6 0.8

XOMAO long term performance overview.The bars show the price performance of XOMAO in the last 1, 2 and 3 years. 1 year 2 years 3 years 2 4 6

The current stock price of XOMAO is 25.4999 USD. In the past month the price decreased by -0.01%. In the past year, price increased by 0.75%.

XOMA ROYALTY CORP - XOMA 8 3/8 PERP / XOMAO Daily stock chart

XOMAO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.07 375.50B
AMGN AMGEN INC 13.01 152.70B
GILD GILEAD SCIENCES INC 14.86 142.76B
VRTX VERTEX PHARMACEUTICALS INC 23.38 101.56B
REGN REGENERON PHARMACEUTICALS 12.56 60.77B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.25B
ARGX ARGENX SE - ADR 80.99 45.95B
ONC BEONE MEDICINES LTD-ADR 6.89 40.63B
INSM INSMED INC N/A 30.67B
BNTX BIONTECH SE-ADR N/A 27.03B
NTRA NATERA INC N/A 23.06B
BIIB BIOGEN INC 8.79 20.62B

About XOMAO

Company Profile

XOMAO logo image XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others. The firm also acquires milestone and royalty revenue streams on late-stage or commercial assets.

Company Info

XOMA ROYALTY CORP - XOMA 8 3/8 PERP

2200 Powell Street, Suite 310

Emeryville CALIFORNIA US

Employees: 13

XOMAO Company Website

XOMAO Investor Relations

Phone: 15102047239

XOMA ROYALTY CORP - XOMA 8 3/8 PERP / XOMAO FAQ

What is the stock price of XOMA ROYALTY CORP - XOMA 8 3/8 PERP today?

The current stock price of XOMAO is 25.4999 USD. The price decreased by -0.03% in the last trading session.


What is the ticker symbol for XOMA ROYALTY CORP - XOMA 8 3/8 PERP stock?

The exchange symbol of XOMA ROYALTY CORP - XOMA 8 3/8 PERP is XOMAO and it is listed on the Nasdaq exchange.


On which exchange is XOMAO stock listed?

XOMAO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for XOMA ROYALTY CORP - XOMA 8 3/8 PERP stock?

10 analysts have analysed XOMAO and the average price target is 51.45 USD. This implies a price increase of 101.77% is expected in the next year compared to the current price of 25.4999. Check the XOMA ROYALTY CORP - XOMA 8 3/8 PERP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is XOMA ROYALTY CORP - XOMA 8 3/8 PERP worth?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a market capitalization of 308.29M USD. This makes XOMAO a Small Cap stock.


How many employees does XOMA ROYALTY CORP - XOMA 8 3/8 PERP have?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) currently has 13 employees.


What are the support and resistance levels for XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a support level at 25.5 and a resistance level at 25.77. Check the full technical report for a detailed analysis of XOMAO support and resistance levels.


Is XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) expected to grow?

The Revenue of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is expected to grow by 78.53% in the next year. Check the estimates tab for more information on the XOMAO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock pay dividends?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a dividend yield of 8.24%. The yearly dividend amount is currently 0.47. Check the full fundamental report for a detailed analysis of XOMAO dividend history, reliability and sustainability.


When does XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) report earnings?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) will report earnings on 2025-11-05.


What is the Price/Earnings (PE) ratio of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO)?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.54).


What is the Short Interest ratio of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?

The outstanding short interest for XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is 0.01% of its float. Check the ownership tab for more information on the XOMAO short interest.


XOMAO Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to XOMAO. When comparing the yearly performance of all stocks, XOMAO is a bad performer in the overall market: 65.07% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

XOMAO Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to XOMAO. XOMAO has a medium profitability rating, but doesn't score so well on its financial health evaluation.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

XOMAO Financial Highlights

Over the last trailing twelve months XOMAO reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS decreased by -38.74% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -7.93%
ROE -19.17%
Debt/Equity 1.11
Chartmill High Growth Momentum
EPS Q2Q%-47.62%
Sales Q2Q%18.39%
EPS 1Y (TTM)-38.74%
Revenue 1Y (TTM)168.71%

XOMAO Forecast & Estimates

10 analysts have analysed XOMAO and the average price target is 51.45 USD. This implies a price increase of 101.77% is expected in the next year compared to the current price of 25.4999.

For the next year, analysts expect an EPS growth of 117.66% and a revenue growth 78.53% for XOMAO


Analysts
Analysts82
Price Target51.45 (101.77%)
EPS Next Y117.66%
Revenue Next Year78.53%

XOMAO Ownership

Ownership
Inst Owners62.65%
Ins Owners1.34%
Short Float %0.01%
Short Ratio0.31